Dr Reddy's Laboratories Ltd Stock News

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and NVIDIA (NVDA), which investors can add to their portfolio for solid gains.

Caterpillar (CAT), Applied Materials (AMAT), Toll Brothers (TOL), Walmart (WMT) and Dr. Reddy's (RDY) could be solid choices for investors amid market weakness.

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), J&J Snack (JJSF) and Granite Ridge (GRNT) are poised to gain.

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Dr. Reddy's Laboratories Ltd. (RDY) remains an attractive investment due to its strong Q4 and FY'23 numbers, exposure to the Indian generics market, and consistent new product launches. RDY is well-po

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

With the market facing myriad pressure points – predominantly stubbornly high inflation along with general anxieties about an incoming recession – the bright side is that investors have options re

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Dr Reddy's Laboratories Ltd (NYSE:RDY ) Q4 2023 Earnings Conference Call May 10, 2023 10:00 AM ET Company Participants Richa Periwal - IR Gunupati Prasad - Co-Chairman Parag Agarwal - CFO Erez Israeli